Amneal And mAbxience Ally On Denosumab In US
Deal Agreed Between Partners On Biosimilar Candidates Referencing Prolia And Xgeva
Amneal has struck a deal with mAbxience to gain US rights to two denosumab biosimilars referencing the Prolia and Xgeva brands that have annual US sales in excess of $4bn.
